LNAI Overview

Lunai Bioworks, Inc is focused on AI-powered biodefense, drug discovery and advanced diagnostics. It is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.

Wall Street analysts forecast LNAI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNAI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lunai Bioworks Inc revenue for the last quarter amounts to 0.00 USD, decreased

Lunai Bioworks Inc. EPS for the last quarter amounts to -0.08 USD, decreased -82.22

Lunai Bioworks Inc (LNAI) has 29 emplpoyees as of March 17 2026.

Today LNAI has the market capitalization of 5.13M USD.